Molecular Cancer Therapeutics Funding
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takenobu, T.
Right arrow Articles by Matsui, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takenobu, T.
Right arrow Articles by Matsui, H.
Vol. 1, 1043-1049, October 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Development of p53 Protein Transduction Therapy Using Membrane-permeable Peptides and the Application to Oral Cancer Cells 1

Toshihiko Takenobu, Kazuhito Tomizawa2, Masayuki Matsushita, Sheng-Tian Li, Akiyoshi Moriwaki, Yun-Fei Lu and Hideki Matsui

Department of Physiology, Graduate School of Medicine and Dentistry, Okayama University, Okayama 700-8558 [T. T., K. T., M. M., S-T. L., A. M., H. M.]; Department of Oral and Maxillofacial Surgery, Kobe City General Hospital, Kobe 650-0046 [T. T.]; and "Protein Therapy," Preventure Program, and Japan Science and Technology Corporation, Okayama 700-8558 [Y-F. L., H. M.], Japan

Recent studies suggest that several proteins can transverse biological membranes through protein transduction. The protein transduction domains of these proteins, 10–16 residues long, have been identified as critical domains for the protein transduction. Poly-arginine peptide also has the ability of protein transduction. Here, we show that the protein delivery system using 11 poly-arginine peptides (11R) is a powerful tool for the transduction of the biologically active tumor suppressor protein, p53, to suppress the proliferation of oral cancer cells. The 11R-fused p53 proteins (11R-p53) effectively penetrated across the plasma membrane of the cancer cells and translocated into the nucleus. The proteins induced the activity of the p21/WAF promoter and inhibited the proliferation of human oral cancer cells, in which the p53 gene was mutated. The effect was equivalent to that of the adenovirus-mediated p53 gene transduction system. Moreover, 11R-p53 enhanced the cisplatin-dependent induction of apoptosis of the cells. These data suggest that this protein transduction method may become a promising cancer therapy.




This article has been cited by other articles:


Home page
StrokeHome page
T. Ogawa, S. Ono, T. Ichikawa, S. Arimitsu, K. Onoda, K. Tokunaga, K. Sugiu, K. Tomizawa, H. Matsui, and I. Date
Novel Protein Transduction Method by Using 11R: An Effective New Drug Delivery System for the Treatment of Cerebrovascular Diseases
Stroke, April 1, 2007; 38(4): 1354 - 1361.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. E. Hansen, L. K. Fischer, G. Chan, S. S. Chang, S. W. Baldwin, R. J. Aragon, J. J. Carter, M. Lilly, R. N. Nishimura, R. H. Weisbart, et al.
Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo
Cancer Res., February 15, 2007; 67(4): 1769 - 1774.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
M. Kitazoe, H. Murata, J. Futami, T. Maeda, M. Sakaguchi, M. Miyazaki, M. Kosaka, H. Tada, M. Seno, N.-h. Huh, et al.
Protein Transduction Assisted by Polyethylenimine-Cationized Carrier Proteins
J. Biochem., June 1, 2005; 137(6): 693 - 701.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Michiue, K. Tomizawa, F.-Y. Wei, M. Matsushita, Y.-F. Lu, T. Ichikawa, T. Tamiya, I. Date, and H. Matsui
The NH2 Terminus of Influenza Virus Hemagglutinin-2 Subunit Peptides Enhances the Antitumor Potency of Polyarginine-mediated p53 Protein Transduction
J. Biol. Chem., March 4, 2005; 280(9): 8285 - 8289.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T.-G. Jin, A. Kurakin, N. Benhaga, K. Abe, M. Mohseni, F. Sandra, K. Song, B. K. Kay, and R. Khosravi-Far
Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5
J. Biol. Chem., December 31, 2004; 279(53): 55594 - 55601.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Tachikawa, O. Schroder, G. Frey, S. P. Briggs, and T. Sera
Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins
PNAS, October 19, 2004; 101(42): 15225 - 15230.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H.-Y. Wu, K. Tomizawa, Y. Oda, F.-Y. Wei, Y.-F. Lu, M. Matsushita, S.-T. Li, A. Moriwaki, and H. Matsui
Critical Role of Calpain-mediated Cleavage of Calcineurin in Excitotoxic Neurodegeneration
J. Biol. Chem., February 6, 2004; 279(6): 4929 - 4940.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.